**Registration and protocol**

**Amendments to information in the protocol.**

In the protocol our outcomes included incidence of infection, hospitalisation for infection and/or mortality from infection, markers of immunological response pre-specified for each vaccine, and adverse events. Our systematic review primary outcome was narrowed down to vaccine efficacy against disease and incident infection.

In the protocol we had initially state that the systematic review protocol will be pre-registered on PROSPERO before data extraction, as per the latest PROSPERO rules. However, this systematic review was not registered in PROSPERO because its primary focus is on identifying plausible ranges for differential vaccine efficacy across high- and low-income settings through descriptive and illustrative analyses, rather than synthesizing direct health outcomes. Nonetheless, the review protocol was developed a priori and conducted in accordance with PRISMA 2020 guidelines to ensure transparency and methodological rigor.

Our systematic review did not include a meta-regression analysis as was stated in the protocol, instead only a meta-analysis was done. Explanatory variables such as climatic (average temperature/peak temperatures), health-related variables (prevalence of relevant pre-specified comorbid diseases (e.g. other gastrointestinal infections), prevalence of incomplete immunization and vaccine program), agent -related (the extent of antigenic variation within and between countries, trial design variables (for individual-level randomisation, the number of protocol violations) were not obtained.